Barclays PLC Sells 124,824 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Barclays PLC lessened its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 50.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 120,221 shares of the company's stock after selling 124,824 shares during the period. Barclays PLC owned approximately 0.18% of EyePoint Pharmaceuticals worth $895,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Franklin Resources Inc. boosted its position in shares of EyePoint Pharmaceuticals by 9.9% during the third quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company's stock valued at $32,056,000 after buying an additional 362,399 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of EyePoint Pharmaceuticals by 1,171.3% during the third quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company's stock valued at $2,970,000 after buying an additional 342,516 shares during the last quarter. Cyndeo Wealth Partners LLC boosted its position in shares of EyePoint Pharmaceuticals by 35.5% during the fourth quarter. Cyndeo Wealth Partners LLC now owns 16,990 shares of the company's stock valued at $127,000 after buying an additional 4,450 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of EyePoint Pharmaceuticals by 40.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,472 shares of the company's stock valued at $108,000 after buying an additional 4,179 shares during the last quarter. Finally, abrdn plc purchased a new position in shares of EyePoint Pharmaceuticals during the fourth quarter valued at approximately $1,719,000. Institutional investors and hedge funds own 99.41% of the company's stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. StockNews.com raised EyePoint Pharmaceuticals to a "sell" rating in a research report on Friday, March 14th. HC Wainwright reissued a "buy" rating and issued a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Finally, Chardan Capital lowered their target price on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, EyePoint Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $25.29.

EyePoint Pharmaceuticals Price Performance

EYPT stock traded down $0.29 on Friday, reaching $5.81. 479,431 shares of the company traded hands, compared to its average volume of 824,374. EyePoint Pharmaceuticals, Inc. has a one year low of $3.91 and a one year high of $13.99. The company has a market cap of $399.79 million, a P/E ratio of -2.91 and a beta of 1.58. The firm has a fifty day simple moving average of $6.02 and a 200-day simple moving average of $7.49.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.65) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.65). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The company had revenue of $24.50 million during the quarter, compared to analyst estimates of $8.84 million. On average, sell-side analysts forecast that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.